Deltex Medical Group PLC said it will launch its next generation TrueVue measurement for blood pressure and blood flow in November this year.
Deltex Medical, a Chichester, England-based blood circulation monitoring system maker, said the launch followed an independent review of the electromagnetic compatibility report on the TrueVue monitor, and subsequent finalisation of the technical file from last Thursday.
Deltex Medical said it will now be able to deploy the TrueVue system for in-hospital evaluations. The system combines measurements of blood flow and blood pressure in a patient across each and every heartbeat in real time, which provides the clinician with validated haemodynamic parameters to test the patient’s cardiac function.
‘It is anticipated that this will take approximately three months and therefore the group is forecasting revenue from new monitor sales to commence in November 2023,’ said Deltex Medical.
The company noted that this was normal practice, and that a medical device is not permitted to be used in a hospital unless it has been CE market, which TrueVue now has.
Chief Executive Officer Andy Mears said: ‘This is against the challenging backdrop of having to conduct work on this project through Covid-19 and dealing with the associated supply chain issues.
‘Initial interest in the new monitor has been positive and we expect the launch to help increase activity levels in all territories ahead of other international regulatory approvals being obtained.’
The company said its new TrueVue system will be the platform for its new non-invasive suprasternal device under development and has broader applications in A&E, general wards, and by paramedics.
Shares in Deltex Medical are suspended. They last traded a 1.10 pence on June 23.
Copyright 2023 Alliance News Ltd. All Rights Reserved
